Messina, Jane L.

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes

Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation

Immunotherapy and Immune ResponsesT-cell and B-cell Immunology

Cited by 852

Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma

Daud, A. I., DeConti, R. C., Andrews, S., Urbas, P., Riker, A. I., Sondak, V. K., Munster, P. N., Sullivan, D. M., Ugen, K. E., Messina, J. L., et al. (2008) · Journal of Clinical Oncology

Microbial Inactivation MethodsImmunotherapy and Immune Responses

Cited by 701

Guidelines of care for the management of basal cell carcinoma

Bichakjian, C., Armstrong, A., Baum, C., Bordeaux, J. S., Brown, M., Busam, K. J., Eisen, D. B., Iyengar, V., Lober, C., Margolis, D. J., et al. (2018) · Journal of the American Academy of Dermatology

Nonmelanoma Skin Cancer StudiesCancer and Skin Lesions

Cited by 499

12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?

Messina, J. L., Fenstermacher, D. A., Eschrich, S., Qu, X., Berglund, A. E., Lloyd, M. C., Schell, M. J., Sondak, V. K., Weber, J. S., & Mulé, J. J. (2012) · Scientific Reports

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 426

High response rate to PD-1 blockade in desmoplastic melanomas

Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., et al. (2018) · Nature

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 338

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

Paraiso, K. H. T., Fedorenko, I. V., Cantini, L. P., Munko, A. C., Hall, M., Sondak, V. K., Messina, J. L., Flaherty, K. T., & Smalley, K. S. M. (2010) · British Journal of Cancer

Melanoma and MAPK PathwaysProtein Tyrosine Phosphatases

Cited by 314

HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy

Emmons, M. F., Faião-Flores, F., Sharma, R., Thapa, R., Messina, J. L., Becker, J. C., Schadendorf, D., Seto, E., Sondak, V. K., Koomen, J. M., et al. (2019) · Cancer Research

Melanoma and MAPK PathwaysHistone Deacetylase Inhibitors Research

Cited by 73

Inhibition of autophagy enhances the effects of the AKT inhibitor MK‐2206 when combined with paclitaxel and carboplatin in BRAF wild‐type melanoma

Rebecca, V. W., Massaro, R. R., Fedorenko, I. V., Sondak, V. K., Anderson, A. R. A., Kim, E., Amaravadi, R. K., Maria‐Engler, S. S., Messina, J. L., Gibney, G. T., et al. (2014) · Pigment Cell & Melanoma Research

Melanoma and MAPK PathwaysAutophagy in Disease and Therapy

Cited by 58

Preexisting Skin-Resident CD8 and γδ T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy

Reinstein, Z. Z., Zhang, Y., Ospina, O. E., Nichols, M. D., Chu, V. A., Pulido, A. D. M., Prieto, K., Nguyen, J. V., Yin, R., Moran Segura, C., et al. (2024) · Cancer Discovery

Polyomavirus and related diseasesCancer Immunotherapy and Biomarkers

Cited by 33